Investigations were carried out on the medicines mastiriphin--intramammary syringes, (Mf) in two variants "A" and "B", meant for the treatment of acute mastitis with cows and also mastiriphin depot--intramammary syringes (Mf-depot), as well as two variants with indications for subclinical mastitis cows, containing both medicines in 10 g with 80,000 VI rifampicin, SEC "Pharmachem". Experiments were carried out for determining the stability of the medicines at different pH. The investigations were carried out with 23 lactating and 22 non-lactating cows. Both the degree of retention and the velocity of elimination of rifampicin from the milk and the lactic secretion. It was proved in vitro that rifampicin is stable in a neutral milk milieu (pH 7) in the course of 24 hours, and while in acid or alkaline milieu it was quickly eliminated Mf "A" in the case of intramammary introduction created high bacteriostatic (therapeutic) concentrations in the milk of the lactating animals till the sixth (eighth hour, whereas Mf "B" and the imported analogue rifamasten, provided twice as high levels of antibiotic. Mf-depot "B" introduced in a intramammary way with non-lactating cows was retained in the lactic secretion between 15 and 20 days. The quarantine time limits for using the milk taken from cows, treated in an intramammary way, proved to be 72 hours.
Download full-text PDF |
Source |
---|
Proc Natl Acad Sci U S A
February 2025
Department of Construction Sciences, Lund University, Lund SE-22100, Sweden.
Preemptive identification of potential failure under loading of engineering structures is a critical challenge. Our study presents an innovative approach to design built-in prefailure indicators within multiscale structural designs with optimized load carrying capabilities utilizing the design freedom of topology optimization. The indicators are engineered to visibly signal load conditions approaching the global critical buckling load at predefined locations.
View Article and Find Full Text PDFAge Ageing
January 2025
Department of Medical Oncology, Koç University Hospital, Davutpaşa Street 34010 Topkapı, Istanbul, Turkey.
Background: Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy, yet they carry a unique spectrum of immune-related adverse events (irAEs). Given the ageing global population and the underrepresentation of older adults in clinical trials for ICIs, we investigated the occurrence and characteristics of irAEs in older versus younger adults as well as among different age subsets within the older adult population.
Methods: We analysed the U.
J Am Soc Nephrol
January 2025
Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030.
Background: Arteriovenous (AV) fistulas are the preferred access for dialysis but have a high incidence of failure. This study aims to understand the crosstalk between skeletal muscle catabolism and AV fistula maturation failure.
Methods: Skeletal muscle metabolism and AV fistula maturation were evaluated in mice with chronic kidney disease (CKD).
Spine Deform
January 2025
Jackie and Gene Autry Children's Orthopedic Center, Children's Hospital Los Angeles, 4650 Sunset Blvd, MS69, Los Angeles, CA, 90027, USA.
Purpose: Determine if Sacral Alar-Iliac (SAI) screw diameter is associated with pelvic fixation failure in pediatric patients with neuromuscular scoliosis (NMS) treated with posterior spinal fusion (PSF).
Methods: NMS patients from a single institution who underwent PSF with bilateral SAI screw fixation from 2010 to 2021 were retrospectively reviewed. Clinical parameters, SAI screw sizes, and radiographic outcomes were analyzed.
J Nephrol
January 2025
Department of Nephrology, Beaumont Hospital, Dublin, Ireland.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is caused primarily by pathogenic variants in the PKD1 and PKD2 genes. Although the type of ADPKD variant can influence disease severity, rare, hypomorphic PKD1 variants have also been reported to modify disease severity or cause biallelic ADPKD. This study examines whether rare, additional, potentially protein-altering, non-pathogenic PKD1 variants contribute to ADPKD phenotypic outcomes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!